Prevention and treatment of respiratory syncytial virus infections (for advances in pediatric infectious diseases).
DeVincenzo
J
J
University of Tennessee, Memphis, USA.
D000305:Adrenal Cortex Hormones / Q000008:administration & dosage; D000818:Animals; D000911:Antibodies, Monoclonal / Q000627:therapeutic use; D000998:Antiviral Agents / Q000008:administration & dosage; D001990:Bronchiolitis, Viral / Q000473:pathology / Q000628:therapy; D001993:Bronchodilator Agents / Q000008:administration & dosage; D001997:Bronchopulmonary Dysplasia / Q000150:complications / Q000628:therapy; D003362:Cost-Benefit Analysis; D004195:Disease Models, Animal; D006330:Heart Defects, Congenital / Q000150:complications; D006801:Humans; D007116:Immunization, Passive / Q000191:economics / Q000379:methods; D016867:Immunocompromised Host; D007223:Infant; D007231:Infant, Newborn; D011024:Pneumonia, Viral / Q000473:pathology / Q000628:therapy; D018357:Respiratory Syncytial Virus Infections / Q000453:epidemiology / Q000473:pathology / Q000517:prevention & control / Q000628:therapy*; D018113:Respiratory Syncytial Virus, Human; D012254:Ribavirin / Q000008:administration & dosage; D014611:Vaccination / Q000191:economics / Q000379:methods
D000305:Adrenal Cortex Hormones; D000911:Antibodies, Monoclonal; D000998:Antiviral Agents; D001993:Bronchodilator Agents; D012254:Ribavirin